Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


First published on July 30, 2008
A more recent version of this article appeared on January 1, 2008
Neuro Oncol 2008, DOI:10.1215/15228517-2008-052
This Article
Right arrow Advance Publication Full Text (PDF)
Right arrow All Versions of this Article:
10/6/1025    most recent
15228517-2008-052v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pichlmeier, U.
Right arrow Articles by Study Group, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Copyright 2008 by the Society for Neuro-Oncology

Received January 9, 2008
Accepted May 11, 2008

Clinical Investigations

Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients

Uwe Pichlmeier 1, Andrea Bink 2, Gabriele Schackert 3, Walter Stummer 4*, ALA Glioma Study Group

1 Medac Gesellschaft für klinische Spezialpräparate mbH, Theaterstr. 6, 22880 Wedel, Germany
2 Institut für Neuroradiologie, J.W. Goethe Universitätsklinikum, Schleusenweg 2-16, 60528 Frankfurt a.M
3 Neurochirurgische Klinik, Universitätsklinikum Carl Gustav Carus, Fetscherstraße 74 01307 Dresden
4 Neurochirurgische Klinik, Heinrich-Heine-Universität, Moorenstr. 5, 40225 Düsseldorf

* To whom correspondence should be addressed. E-mail: stummer{at}uni-duesseldorf.de.


   Abstract

Introduction: The benefit of cytoreductive surgery for glioblastoma multiforme (GBM) is unclear and selection bias in past series has been observed. The ALA study investigated the influence of fluorescence-guided resections on outcome and generated an extensive database of GBM patients with optimized resections. We evaluated whether the RTOG recursive partitioning analysis (RPA) would predict survival of these patients and whether there was any benefit from extensive resections depending on RPA class.

Patients and Methods: 243 per protocol patients with newly diagnosed GBM were operated with or without ALA and treated by radiotherapy. Postoperative MR-imaging was obtained in all patients. Patients were allocated into RTOG-RPA classes III to V based on age, Karnofsky Performance Status, neurological condition and mental status (as derived from the National Institute of Health stroke score).

Results: Median overall survival among RPA classes III, IV, and V was 17.8, 14.7 and 10.7 months, respectively, with 2-year survival rates of 26%, 12%, and 7% (p=0.0007). Stratified for degree of resection, survival of patients with complete resections was longer in RPA classes IV and V (17.7 vs. 12.9, p=0.0015, and 13.7 vs. 10.4, p=0.0398; 2-year rates: 21.0 vs. 4.4% and 11.1 vs. 2.6%, respectively), but not clearly in the small subgroup of RPA class III patients (19.3 vs. 16.3 months, p=0.14).

Conclusion: Survival of patients from the ALA study is correctly predicted by the RTOG-RPA classes. Differences in survival depending on resection status, especially in RPA classes IV and V, support a causal influence of resection on survival.

Key Words: resection, survival, glioblastoma multiforme, recursive partitioning analysis, aminolevulinic acid


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


Copyright 2008 by Society for Neuro-Oncology